Univariate analysis of demographic and clinical features at diagnosis associated with treatment abandonment
| Univariate analysis | ||||
| Feature | Category | Patients not abandoning treatment n (%) | Patients abandoning treatment n (%) | P value |
| Age (years) | <1 | 34 (1.3) | 3 (3.6) | 0.0151 |
| 1–9 | 2233 (87.3) | 64 (77.1) | ||
| ≥10 | 291 (11.4) | 16 (19.3) | ||
| Sex | Male | 1512 (59.1) | 46 (55.4) | 0.4989 |
| Female | 1046 (40.9) | 37 (44.6) | ||
| Leucocyte count (×109/L) | <50 | 2042 (79.8) | 59 (71.1) | 0.0707 |
| ≥50 | 516 (20.2) | 24 (28.9) | ||
| CNS status | CNS-1 | 2401 (93.9) | 76 (91.6) | 0.0681 |
| CNS-2 | 32 (1.3) | 0 | ||
| CNS-3 | 10 (0.4) | 2 (2.4) | ||
| Traumatic without blasts | 105 (4.1) | 4 (4.8) | ||
| Intracranial mass | 10 (0.4) | 1 (1.2) | ||
| Lineage | B | 2329 (91.0) | 70 (84.3) | 0.0502 |
| T | 229 (9.0) | 13 (15.7) | ||
| Risk group* | Low | 1697 (66.3) | 39 (47.0) | 0.0004 |
| Standard/high | 861 (33.7) | 44 (53.0) | ||
| CR status | CR | 2515 (98.3) | 65 (78.3) | <0.0001 |
| No CR | 43 (1.7) | 18 (21.7)† | ||
| MRD, day 19 | Negative | 1155 (47.3) | 24 (32.4) | 0.0127 |
| Positive | 1289 (52.7) | 50 (67.6) | ||
| MRD, day 46 | Negative | 2005 (84.7) | 35 (60.3) | <0.0001 |
| Positive | 362 (15.3) | 23 (39.7) | ||
| Molecular abnormalities | T lineage | 229 (9.0) | 13 (15.7) | 0.0001 |
| BCR-ABL1 fusion | 101 (3.9) | 7 (8.4) | ||
| TEL-AML1 fusion | 496 (19.4) | 9 (10.8) | ||
| E2A-PBX1 fusion | 103 (4.0) | 3 (3.6) | ||
| MLL rearrangement | 58 (2.3) | 7 (8.4) | ||
| PDGFRB rearrangement | 11 (0.4) | 1 (1.2) | ||
| B lineage, other | 1557 (60.9) | 42 (50.6) | ||
| Not done | 3 (0.1) | 1 (1.2) | ||
| Region‡ | High income | 1445 (56.5) | 34 (41.0) | <0.0001 |
| Middle income | 827 (32.3) | 26 (31.3) | ||
| Low income | 286 (11.2) | 23 (27.7) | ||
*Initial risk determined at diagnosis.
†Eighteen patients abandoned treatment before end of induction; they were deemed ‘no CR.’
‡High-income region, upper third of the average per capita disposable income (PCDI) in 2016; middle-income region, middle third of the average PCDI; low-income region, lower third of the average PCDI.
CNS, central nervous system; CR, complete remission; MRD, minimal residual disease.